Advanced search
Publication Cover
Cancer Biology & Therapy Volume 17, 2016 - Issue 7
Submit an article Journal homepage
1,417
Views
16
CrossRef citations to date
0
Altmetric
Research Paper

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma

Katelyn G. PonderCancer Biology Graduate Program, Winship Cancer Institute of Emory University, Atlanta, GA, USA
,
Shannon M. MatulisDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
,
Sadae HitosugiDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
,
Vikas A. GuptaDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
,
Cathy SharpWinship Cancer Institute of Emory University, Atlanta, GA, USA
,
Francis BurrowsTragara Pharmaceuticals, San Diego, CA, USA
,
Ajay K. NookaDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA;Winship Cancer Institute of Emory University, Atlanta, GA, USA
,
Jonathan L. KaufmanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA;Winship Cancer Institute of Emory University, Atlanta, GA, USA
,
Sagar LonialDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA;Winship Cancer Institute of Emory University, Atlanta, GA, USA
&
Lawrence H. BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA;Winship Cancer Institute of Emory University, Atlanta, GA, USACorrespondence[email protected]
 show all
Pages 769-777 | Received 29 Jul 2015, Accepted 12 May 2016, Published online: 31 May 2016

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jeroen E Guikema, Martine Amiot & Eric Eldering. (2017) Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opinion on Therapeutic Targets 21:8, pages 767-779.
Read now

Articles from other publishers (15)

Danai Dima, Mark Orland, Fauzia Ullah, Faiz Anwer, Sandra Mazzoni, Shahzad Raza, Chakra P. Chaulagain, Christy Samaras, Jason Valent, Louis Williams & Jack Khouri. (2023) Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 23:11, pages 857-860.
Crossref
Peddaguravagari Mounika, Bannimath Gurupadayya, Honnavalli Yogish Kumar & Bannimath Namitha. (2023) An Overview of CDK Enzyme Inhibitors in Cancer Therapy. Current Cancer Drug Targets 23:8, pages 603-619.
Crossref
Shady I. Tantawy, Natalia Timofeeva, Aloke Sarkar & Varsha Gandhi. (2023) Targeting MCL-1 protein to treat cancer: opportunities and challenges. Frontiers in Oncology 13.
Crossref
Manzoor Ahmad Mir & Umar Y. Mir. 2023. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer 269 289 .
Yu Guo, Lin Zhang, Ning Zhang, Luohai Chen, Qiuyun Luo, Man Liu, Dajun Yang & Jie Chen. (2022) Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms. Endocrine 78:1, pages 159-168.
Crossref
Zhi Huang, Tianqi Wang, Cheng Wang & Yan Fan. (2022) CDK9 inhibitors in cancer research. RSC Medicinal Chemistry 13:6, pages 688-710.
Crossref
Deendyal Bhurta & Sandip B. Bharate. (2021) Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Medicinal Research Reviews 42:2, pages 654-709.
Crossref
Luciano J. Costa, Faith E. DaviesGregory P. MonohanTibor KovacsovicsNicholas BurwickAndrzej JakubowiakJonathan L. Kaufman, Wan-Jen HongMonique Dail, Ahmed Hamed SalemXiaoqing YangAbdullah A. MasudWijith MunasingheJeremy A. RossOrlando F. BuenoShaji K. Kumar & Edward A. Stadtmauer. (2021) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Advances 5:19, pages 3748-3759.
Crossref
Simone Claudiani, Clinton C. Mason, Dragana Milojkovic, Andrea Bianchi, Cristina Pellegrini, Antinisca Di Marco, Carme R. Fiol, Mark Robinson, Kanagaraju Ponnusamy, Katya Mokretar, Avirup Chowdhury, Michael Albert, Alistair G. Reid, Michael W. Deininger, Kikkeri Naresh, Jane F. Apperley & Jamshid S. Khorashad. (2021) Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. Cancers 13:19, pages 4863.
Crossref
Jing Wu, Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung, Yu-Ting Su, Ying Pang, Guangyang Yu, Madison K. Butler, Tito R. Mendoza, Elizabeth Vera, Salman Ahmad, Christine Bryla, Matthew Lindsley, Ewa Grajkowska, Kelly Mentges, Lisa Boris, Ramya Antony, Nancy Garren, Christine Siegel, Nicole Lollo, Christine Cordova, Orwa Aboud, Brett J. Theeler, Eric M. Burton, Marta Penas-Prado, Heather Leeper, Javier Gonzales, Terri S. Armstrong, Katherine R. Calvo, William D. Figg, Douglas B. Kuhns, John I. Gallin & Mark R. Gilbert. (2021) Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research 27:12, pages 3298-3306.
Crossref
Andrew H. Wei, Andrew W. Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Roland B. Walter, Sean Caenepeel, Paul Hughes, Zach McIver, Khalid Mezzi, Phuong Khanh Morrow & Anthony Stein. (2020) Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews 44, pages 100672.
Crossref
Shaji K. Kumar. (2019) Targeted Management Strategies in Multiple Myeloma. The Cancer Journal 25:1, pages 59-64.
Crossref
Anke Maes, Eline Menu, Kim De Veirman, Ken Maes, Karin Vanderkerken & Elke De Bruyne. (2017) The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget 8:52, pages 90501-90520.
Crossref
Shardule P. Shah, Ajay K. Nooka, Sagar Lonial & Lawrence H. Boise. (2017) TG02 inhibits proteasome inhibitor–induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood Advances 1:21, pages 1848-1853.
Crossref
Yu Zhang, Liang Zhou, Yun Leng, Yun Dai, Robert Z. Orlowski & Steven Grant. (2017) Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8:35, pages 59476-59491.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.